This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bryan, E. J. Articles by Campbell, I. G. Search for Related Content PubMed PubMed Citation Articles by Bryan, E. J. Articles by Campbell, I. G.

Localization of an Ovarian Cancer Tumor Suppressor Gene to a 0.5-cM Region between D22S284 and CYP2D, on Chromosome 22q¹

Obstetrics and Gynaecology, University of Southampton, Princess Anne Hospital, Coxford Road, Southampton SO16 5YA [E. J. B., R. H. W., M. D., I. G. C.]; and Department of Histopathology, Southampton General Hospital, Southampton [A. H.], United Kingdom; and Division of Medical Genetics, Department of Medicine, Montreal General Hospital, Montreal, Quebec, Canada H3G 1A4 [W. D. F.]

The detection of loss of heterozygosity, indicative of the presence of a tumor suppressor gene, has been reported to occur frequently on chromosome 22q in human ovarian cancer. In this study, 110 sporadic ovarian tumors were analyzed using 8 polymorphic loci to define a minimum region of loss. Fifty-eight (53%) tumors showed loss of heterozygosity, and of these 6 exhibited partial loss, enabling the identification of two candidate tumor suppressor gene loci. One region, of less than 0.5 cM, is flanked by D22S284 and CYP2D, and a second region lies distal to D22S276. Analysis of loss of heterozygosity with respect to grade and stage suggests that chromosome 22q loss of heterozygosity is of more relevance in tumor progression rather than initiation.

¹ E. J. B. is funded by the Wessex Cancer Trust, and R. H. W. is funded by WellBeing. This work is also supported by the Royal Society.

² To whom requests for reprints should be addressed.

Received 11/24/95. Accepted 12/27/95.

This article has been cited by other articles:

				J. L. Bearfoot, D. Y.H. Choong, K. L. Gorringe, and I. G. Campbell Genetic Analysis of Cancer-Implicated MicroRNA in Ovarian Cancer Clin. Cancer Res., November 15, 2008; 14(22): 7246 - 7250. [Abstract] [Full Text] [PDF]

				S. Jacobs, E. R. Thompson, Y. Nannya, G. Yamamoto, R. Pillai, S. Ogawa, D. K. Bailey, and I. G. Campbell Genome-Wide, High-Resolution Detection of Copy Number, Loss of Heterozygosity, and Genotypes from Formalin-Fixed, Paraffin-Embedded Tumor Tissue Using Microarrays Cancer Res., March 15, 2007; 67(6): 2544 - 2551. [Abstract] [Full Text] [PDF]

				M. Wirtenberger, S. Tchatchou, K. Hemminki, J. Schmutzhard, C. Sutter, R. K. Schmutzler, A. Meindl, B. Wappenschmidt, M. Kiechle, N. Arnold, et al. Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer Carcinogenesis, November 1, 2006; 27(11): 2201 - 2208. [Abstract] [Full Text] [PDF]

				A. Wild, P. Langer, A. Ramaswamy, B. Chaloupka, and D. K. Bartsch A Novel Insulinoma Tumor Suppressor Gene Locus on Chromosome 22q with Potential Prognostic Implications J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5782 - 5787. [Abstract] [Full Text] [PDF]

				A. Castells, J. F. Gusella, V. Ramesh, and A. K. Rustgi A Region of Deletion on Chromosome 22q13 Is Common to Human Breast and Colorectal Cancers Cancer Res., June 1, 2000; 60(11): 2836 - 2839. [Abstract] [Full Text] [PDF]